Literature DB >> 31451973

Prediction of idiopathic pulmonary fibrosis progression using early quantitative changes on CT imaging for a short term of clinical 18-24-month follow-ups.

Grace Hyun J Kim1,2, Stephan S Weigt3, John A Belperio3, Matthew S Brown4, Yu Shi5, Joshua H Lai4, Jonathan G Goldin4.   

Abstract

OBJECTIVE: High-resolution computed tomography (HRCT) plays an indispensable role in the diagnosis of idiopathic pulmonary fibrosis (IPF). Due to unpredictability in progression and the short median survival of 2-5 years, it is critical to delineate the patients with rapid progression. The aim is to evaluate the predictability of IPF progression using the early quantitative changes.
METHODS: Automated texture-based quantitative lung fibrosis (QLF) was calculated from the anonymized HRCT. Two datasets were collected retrospectively: (1) a pilot study of 35 subjects with three sequential scans (baseline and 6 and 12 months) to obtain a threshold, where visual assessments were stable at 6 months but worsened at 12 months; (2) 157 independent subjects to test the threshold. Landmark Cox regressions were used to compare the progression-free survival (PFS) defined by pulmonary function using the threshold from the early changes in QLF. C-indexes were reported as estimations of the concordance of prediction.
RESULTS: A threshold of 4% QLF change at 6 months corresponded to the mean change that worsened on HRCT visually at 12 months from the pilot study. Using the threshold, significant differences were found in the independent dataset (hazard ratio (HZ) = 5.92, p = 0.001 by Cox model, C-index = 0.71 at the most severe lobe; and HZ = 3.22, p = 0.012, C-index = 0.68 in the whole lung). Median PFS was 11.9 months for subjects with ≥ 4% changes, whereas median PFS was greater than 18 months for subjects with < 4% changes at the most severe lobe.
CONCLUSION: Early structural changes on HRCT using a quantitative score can predict progression in lung function. KEY POINTS: • Changes on HRCT using quantitative texture-based scores can play a pivotal role for providing information and an aid tool for timely management decision for patients with IPF. • Quantitative changes on HRCT of 4% or more, which matched 6-month prior changes with visual assessment of worsening, can play a pivotal role for providing prediction of clinical progression by 3-5 folds higher in the next incidence, compared with those of subjects with less than 4% changes. • Early structural changes of 4% or more in a paired HRCT scans derived by quantitative scores can predict the progression in lung function in 1-2 years in subjects with IPF, which is critical information for timely management decision for subjects with IPF where the median survival is 2 to 5 years.

Entities:  

Keywords:  Idiopathic pulmonary fibrosis; Interstitial lung disease; Prediction; Progressive; Quantitative evaluation

Mesh:

Year:  2019        PMID: 31451973     DOI: 10.1007/s00330-019-06402-6

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  31 in total

Review 1.  Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases.

Authors:  Vincent Cottin; Nikhil A Hirani; David L Hotchkin; Anoop M Nambiar; Takashi Ogura; María Otaola; Dirk Skowasch; Jong Sun Park; Hataya K Poonyagariyagorn; Wim Wuyts; Athol U Wells
Journal:  Eur Respir Rev       Date:  2018-12-21

2.  Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.

Authors:  Roland M du Bois; Derek Weycker; Carlo Albera; Williamson Z Bradford; Ulrich Costabel; Alex Kartashov; Lisa Lancaster; Paul W Noble; Ganesh Raghu; Steven A Sahn; Javier Szwarcberg; Michiel Thomeer; Dominique Valeyre; Talmadge E King
Journal:  Am J Respir Crit Care Med       Date:  2011-08-15       Impact factor: 21.405

3.  Computed Tomographic Biomarkers in Idiopathic Pulmonary Fibrosis. The Future of Quantitative Analysis.

Authors:  Xiaoping Wu; Grace H Kim; Margaret L Salisbury; David Barber; Brian J Bartholmai; Kevin K Brown; Craig S Conoscenti; Jan De Backer; Kevin R Flaherty; James F Gruden; Eric A Hoffman; Stephen M Humphries; Joseph Jacob; Toby M Maher; Ganesh Raghu; Luca Richeldi; Brian D Ross; Rozsa Schlenker-Herceg; Nicola Sverzellati; Athol U Wells; Fernando J Martinez; David A Lynch; Jonathan Goldin; Simon L F Walsh
Journal:  Am J Respir Crit Care Med       Date:  2019-01-01       Impact factor: 21.405

4.  A computer-aided diagnosis system for quantitative scoring of extent of lung fibrosis in scleroderma patients.

Authors:  H G Kim; D P Tashkin; P J Clements; G Li; M S Brown; R Elashoff; D W Gjertson; F Abtin; D A Lynch; D C Strollo; J G Goldin
Journal:  Clin Exp Rheumatol       Date:  2010-11-03       Impact factor: 4.473

5.  FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis.

Authors:  Ganesh Raghu; Mary Beth Scholand; João de Andrade; Lisa Lancaster; Yolanda Mageto; Jonathan Goldin; Kevin K Brown; Kevin R Flaherty; Mark Wencel; Jack Wanger; Thomas Neff; Frank Valone; John Stauffer; Seth Porter
Journal:  Eur Respir J       Date:  2016-03-10       Impact factor: 16.671

6.  Radiological versus histological diagnosis in UIP and NSIP: survival implications.

Authors:  K R Flaherty; E L Thwaite; E A Kazerooni; B H Gross; G B Toews; T V Colby; W D Travis; J A Mumford; S Murray; A Flint; J P Lynch; F J Martinez
Journal:  Thorax       Date:  2003-02       Impact factor: 9.139

7.  A multidimensional index and staging system for idiopathic pulmonary fibrosis.

Authors:  Brett Ley; Christopher J Ryerson; Eric Vittinghoff; Jay H Ryu; Sara Tomassetti; Joyce S Lee; Venerino Poletti; Matteo Buccioli; Brett M Elicker; Kirk D Jones; Talmadge E King; Harold R Collard
Journal:  Ann Intern Med       Date:  2012-05-15       Impact factor: 25.391

8.  A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.

Authors:  Talmadge E King; Williamson Z Bradford; Socorro Castro-Bernardini; Elizabeth A Fagan; Ian Glaspole; Marilyn K Glassberg; Eduard Gorina; Peter M Hopkins; David Kardatzke; Lisa Lancaster; David J Lederer; Steven D Nathan; Carlos A Pereira; Steven A Sahn; Robert Sussman; Jeffrey J Swigris; Paul W Noble
Journal:  N Engl J Med       Date:  2014-05-18       Impact factor: 91.245

9.  Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.

Authors:  Luca Richeldi; Roland M du Bois; Ganesh Raghu; Arata Azuma; Kevin K Brown; Ulrich Costabel; Vincent Cottin; Kevin R Flaherty; David M Hansell; Yoshikazu Inoue; Dong Soon Kim; Martin Kolb; Andrew G Nicholson; Paul W Noble; Moisés Selman; Hiroyuki Taniguchi; Michèle Brun; Florence Le Maulf; Mannaïg Girard; Susanne Stowasser; Rozsa Schlenker-Herceg; Bernd Disse; Harold R Collard
Journal:  N Engl J Med       Date:  2014-05-18       Impact factor: 91.245

10.  Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.

Authors:  Steven D Nathan; Carlo Albera; Williamson Z Bradford; Ulrich Costabel; Roland M du Bois; Elizabeth A Fagan; Robert S Fishman; Ian Glaspole; Marilyn K Glassberg; Kenneth F Glasscock; Talmadge E King; Lisa Lancaster; David J Lederer; Zhengning Lin; Carlos A Pereira; Jeffrey J Swigris; Dominique Valeyre; Paul W Noble; Athol U Wells
Journal:  Thorax       Date:  2016-03-11       Impact factor: 9.139

View more
  14 in total

Review 1.  Quantitative Computed Tomography: What Clinical Questions Can it Answer in Chronic Lung Disease?

Authors:  Marcelo Cardoso Barros; Stephan Altmayer; Alysson Roncally Carvalho; Rosana Rodrigues; Matheus Zanon; Tan-Lucien Mohammed; Pratik Patel; Al-Ani Mohammad; Borna Mehrad; Jose Miguel Chatkin; Bruno Hochhegger
Journal:  Lung       Date:  2022-06-25       Impact factor: 3.777

2.  Quantitative analysis of high-resolution computed tomography features of idiopathic pulmonary fibrosis: a structure-function correlation study.

Authors:  Haishuang Sun; Min Liu; Han Kang; Xiaoyan Yang; Peiyao Zhang; Rongguo Zhang; Huaping Dai; Chen Wang
Journal:  Quant Imaging Med Surg       Date:  2022-07

3.  Screening for idiopathic pulmonary fibrosis using comorbidity signatures in electronic health records.

Authors:  Dmytro Onishchenko; Robert J Marlowe; Che G Ngufor; Louis J Faust; Andrew H Limper; Gary M Hunninghake; Fernando J Martinez; Ishanu Chattopadhyay
Journal:  Nat Med       Date:  2022-09-29       Impact factor: 87.241

Review 4.  Origins of and lessons from quantitative functional X-ray computed tomography of the lung.

Authors:  Eric A Hoffman
Journal:  Br J Radiol       Date:  2022-03-01       Impact factor: 3.629

5.  Effects of Nintedanib on Quantitative Lung Fibrosis Score in Idiopathic Pulmonary Fibrosis.

Authors:  Lisa Lancaster; Jonathan Goldin; Matthias Trampisch; Grace Hyun Kim; Jonathan Ilowite; Lawrence Homik; David L Hotchkin; Mitchell Kaye; Christopher J Ryerson; Nesrin Mogulkoc; Craig S Conoscenti
Journal:  Open Respir Med J       Date:  2020-09-22

Review 6.  Idiopathic Pulmonary Fibrosis: Best Practice in Monitoring and Managing a Relentless Fibrotic Disease.

Authors:  Wim A Wuyts; Marlies Wijsenbeek; Benjamin Bondue; Demosthenes Bouros; Paul Bresser; Carlos Robalo Cordeiro; Ole Hilberg; Jesper Magnusson; Effrosyni D Manali; António Morais; Spyridon Papiris; Saher Shaker; Marcel Veltkamp; Elisabeth Bendstrup
Journal:  Respiration       Date:  2019-12-12       Impact factor: 3.580

7.  A study design for statistical learning technique to predict radiological progression with an application of idiopathic pulmonary fibrosis using chest CT images.

Authors:  Grace Hyun J Kim; Yu Shi; Wenxi Yu; Weng Kee Wong
Journal:  Contemp Clin Trials       Date:  2021-03-19       Impact factor: 2.226

Review 8.  [Artificial intelligence in lung imaging].

Authors:  F Prayer; S Röhrich; J Pan; J Hofmanninger; G Langs; H Prosch
Journal:  Radiologe       Date:  2020-01       Impact factor: 0.635

9.  1024-pixel image matrix for chest CT - Impact on image quality of bronchial structures in phantoms and patients.

Authors:  André Euler; Katharina Martini; Bettina Baessler; Matthias Eberhard; Friederike Schoeck; Hatem Alkadhi; Thomas Frauenfelder
Journal:  PLoS One       Date:  2020-06-16       Impact factor: 3.240

Review 10.  Imaging of COVID-19 pneumonia: Patterns, pathogenesis, and advances.

Authors:  Prashant Nagpal; Sabarish Narayanasamy; Aditi Vidholia; Junfeng Guo; Kyung Min Shin; Chang Hyun Lee; Eric A Hoffman
Journal:  Br J Radiol       Date:  2020-08-06       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.